Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women
Status: Archived
Group Health Cooperative Center for Health Studies
mi
from
Seattle, WA
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women
Status: Archived
Updated: 1/1/1970
Group Health Cooperative Center for Health Studies
mi
from
Seattle, WA
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Cell Mediated Immunity in Older Adults
EVALUATION OF CELL-MEDIATED IMMUNITY AND ANTIBODY RESPONSE TO INFLUENZA VACCINATION AND CORRELATES OF PROTECTION IN SENIORS
Status: Archived
Vanderbilt University Medical Center
mi
from
Nashville, TN
Cell Mediated Immunity in Older Adults
EVALUATION OF CELL-MEDIATED IMMUNITY AND ANTIBODY RESPONSE TO INFLUENZA VACCINATION AND CORRELATES OF PROTECTION IN SENIORS
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Nashville, TN
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza
Status: Archived
Vital Clinical Research
mi
from
DeSoto, TX
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza
Status: Archived
Updated: 1/1/1970
Vital Clinical Research
mi
from
DeSoto, TX
Real-time Influenza Vaccine Surveillance
Real-time Influenza Vaccine Surveillance: FLUNET
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Real-time Influenza Vaccine Surveillance
Real-time Influenza Vaccine Surveillance: FLUNET
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Louisville, KY
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Louisville, KY
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Henderson, NV
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Henderson, NV
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Providence, RI
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Providence, RI
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Study of Quadrivalent Influenza Vaccine Among Children
Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children
Status: Archived
Vaccine Research Unit Room 3-5000
mi
from
Rochester, NY
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children
Status: Archived
Updated: 1/1/1970
Vaccine Research Unit Room 3-5000
mi
from
Rochester, NY
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Miller Children's Hospital Long Beach
mi
from
Long Beach, CA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Miller Children's Hospital Long Beach
mi
from
Long Beach, CA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
UC San Diego Medical Center
mi
from
San Diego, CA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
mi
from
San Diego, CA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Children's Doctor
mi
from
Houston, TX
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Children's Doctor
mi
from
Houston, TX
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Duke University Hospital
mi
from
Durham, NC
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Duke University Hospital
mi
from
Durham, NC
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Health Management Training to Enhance Influenza Vaccine Immunogenicity
Health Management Training to Enhance Influenza Vaccine Immunogenicity
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Health Management Training to Enhance Influenza Vaccine Immunogenicity
Health Management Training to Enhance Influenza Vaccine Immunogenicity
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
T-cell Response-Flu Risk in Older Adults
T-cell Responses Predict Influenza Risk in Older Adults
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
T-cell Response-Flu Risk in Older Adults
T-cell Responses Predict Influenza Risk in Older Adults
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated:  12/31/1969
Uni of Alabama At Birmingham; Division of Nephrology
mi
from
Birmingham, AL
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated: 12/31/1969
Uni of Alabama At Birmingham; Division of Nephrology
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham; Pediatric Nephrology
mi
from
Birmingham, AL
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham; Pediatric Nephrology
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated:  12/31/1969
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated: 12/31/1969
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated:  12/31/1969
Providence Clinical Research
mi
from
Burbank, CA
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated: 12/31/1969
Providence Clinical Research
mi
from
Burbank, CA
Click here to add this to my saved trials
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated:  12/31/1969
AIDS Research Alliance
mi
from
Los Angeles, CA
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status: Enrolling
Updated: 12/31/1969
AIDS Research Alliance
mi
from
Los Angeles, CA
Click here to add this to my saved trials